141 related articles for article (PubMed ID: 12168413)
21. Imatinib dose escalation to achieve molecular responses in patients with chronic myeloid leukemia in late chronic phase.
Stagno F; Vigneri P; Del Fabro V; Stella S; Massimino M; Berretta S; Messina A; Di Raimondo F
Leuk Res; 2009 Jun; 33(6):e17. PubMed ID: 19036439
[No Abstract] [Full Text] [Related]
22. Imatinib for chronic myeloid leukemia: the impact of its effectiveness and long-term side effects.
Smith BD
J Natl Cancer Inst; 2011 Apr; 103(7):527-9. PubMed ID: 21422404
[No Abstract] [Full Text] [Related]
23. Autotransplantation for chronic myeloid leukemia: is it useful?
Olavarria E
Haematologica; 2002 Jan; 87(1):3-6. PubMed ID: 11801458
[No Abstract] [Full Text] [Related]
24. Chronic myeloid leukemia.
Singhal N; Bapsy PP; Babu KG; George J
J Assoc Physicians India; 2004 May; 52():410-6. PubMed ID: 15656033
[TBL] [Abstract][Full Text] [Related]
25. Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase.
O'Brien S; Giles F; Talpaz M; Cortes J; Rios MB; Shan J; Thomas D; Andreeff M; Kornblau S; Faderl S; Garcia-Manero G; White K; Mallard S; Freireich E; Kantarjian HM
Cancer; 2003 Sep; 98(5):888-93. PubMed ID: 12942553
[TBL] [Abstract][Full Text] [Related]
26. Treatment options for newly diagnosed patients with chronic myeloid leukemia.
Maness LJ; McSweeney PA
Curr Hematol Rep; 2004 Jan; 3(1):54-61. PubMed ID: 14695851
[TBL] [Abstract][Full Text] [Related]
27. Chronic myeloid leukaemia and hairy cell leukaemia coexisting in a single patient: difficulties at diagnosis and rational of the therapeutic strategy.
Orciuolo E; Fazzi R; Galimberti S; Testi C; Azzara' A; Carulli G; Petrini M
Leuk Res; 2006 Mar; 30(3):349-53. PubMed ID: 16182365
[TBL] [Abstract][Full Text] [Related]
28. Imatinib: new indication. Chronic myeloid leukaemia, first-line option: favourable findings to be confirmed.
Prescrire Int; 2003 Dec; 12(68):216-8. PubMed ID: 14986692
[TBL] [Abstract][Full Text] [Related]
29. Does early imatinib-induced myelosuppression predict hematologic responses in patients with advanced-phase chronic myeloid leukemia?
Cashen A; DiPersio JF; Khoury H
J Clin Oncol; 2003 Nov; 21(22):4255-6. PubMed ID: 14615462
[No Abstract] [Full Text] [Related]
30. Long-term survival estimates for imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia.
Anstrom KJ; Reed SD; Allen AS; Glendenning GA; Schulman KA
Cancer; 2004 Dec; 101(11):2584-92. PubMed ID: 15493041
[TBL] [Abstract][Full Text] [Related]
31. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up.
Lahaye T; Riehm B; Berger U; Paschka P; Müller MC; Kreil S; Merx K; Schwindel U; Schoch C; Hehlmann R; Hochhaus A
Cancer; 2005 Apr; 103(8):1659-69. PubMed ID: 15747376
[TBL] [Abstract][Full Text] [Related]
32. Imatinib in combination with cytarabine for the treatment of Philadelphia-positive chronic myelogenous leukemia chronic-phase patients: rationale and design of phase I/II trials.
Guilhot F; Gardembas M; Rousselot P; Tulliez M; Vigier M; Buzyn A; Rigal-Huguet F; Legros L; Michallet M; Berthou C; Najman A; Maloisel F; Mahon FX; Facon T; Berthaud P; Guilhot J;
Semin Hematol; 2003 Apr; 40(2 Suppl 2):92-7. PubMed ID: 12783382
[TBL] [Abstract][Full Text] [Related]
33. Revised advice on use of imatinib for chronic myeloid leukaemia.
Campbell K
Nurs Times; 2003 Oct 14-20; 99(41):20-1. PubMed ID: 14603651
[TBL] [Abstract][Full Text] [Related]
34. Cytogenetic and fluorescence in situ hybridization monitoring in Ph+ Chronic Myeloid Leukemia patients treated with imatinib mesylate.
Fugazza G; Miglino M; Bruzzone R; Quintino S; Gatti AM; Grasso R; Gobbi M; Frassoni F; Sessarego M
J Exp Clin Cancer Res; 2004 Jun; 23(2):295-9. PubMed ID: 15354415
[TBL] [Abstract][Full Text] [Related]
35. The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase.
Sneed TB; Kantarjian HM; Talpaz M; O'Brien S; Rios MB; Bekele BN; Zhou X; Resta D; Wierda W; Faderl S; Giles F; Cortes JE
Cancer; 2004 Jan; 100(1):116-21. PubMed ID: 14692031
[TBL] [Abstract][Full Text] [Related]
36. Imatinib mesylate in Philadelphia chromosome-positive leukemia of childhood.
Kolb EA; Pan Q; Ladanyi M; Steinherz PG
Cancer; 2003 Dec; 98(12):2643-50. PubMed ID: 14669284
[TBL] [Abstract][Full Text] [Related]
37. Practical management of patients with chronic myeloid leukemia receiving imatinib.
Deininger MW; O'Brien SG; Ford JM; Druker BJ
J Clin Oncol; 2003 Apr; 21(8):1637-47. PubMed ID: 12668652
[TBL] [Abstract][Full Text] [Related]
38. Imatinib therapy in chronic myeloid leukemia.
Crossman LC; O'Brien SG
Hematol Oncol Clin North Am; 2004 Jun; 18(3):605-17, viii. PubMed ID: 15271395
[TBL] [Abstract][Full Text] [Related]
39. Imatinib mesylate therapy of chronic phase chronic myeloid leukemia resistant or intolerant to interferon: results and prognostic factors for response and progression-free survival in 150 patients.
Cervantes F; Hernández-Boluda JC; Steegmann JL; Conde E; Alvarez-Larrán A; López-Jiménez J; Osorio S; Villalón L; Camós M; García-Conde J; Odriozola J
Haematologica; 2003 Oct; 88(10):1117-22. PubMed ID: 14555307
[TBL] [Abstract][Full Text] [Related]
40. Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alpha: 5-year outcome.
Palandri F; Iacobucci I; Castagnetti F; Testoni N; Poerio A; Amabile M; Breccia M; Intermesoli T; Iuliano F; Rege-Cambrin G; Tiribelli M; Miglino M; Pane F; Saglio G; Martinelli G; Rosti G; Baccarani M;
Haematologica; 2008 May; 93(5):770-4. PubMed ID: 18367490
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
